CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · IEX Real-Time Price · USD
55.07
+1.26 (2.34%)
At close: May 2, 2024, 4:00 PM
55.27
+0.20 (0.36%)
After-hours: May 2, 2024, 7:59 PM EDT
CRISPR Therapeutics AG Revenue
In the year 2023, CRISPR Therapeutics AG had annual revenue of $371.21M with 30,885.48% growth. Revenue in the quarter ending December 31, 2023 was $201.21M with 3,353,333.33% year-over-year growth.
Revenue (ttm)
$371.21M
Revenue Growth
+30,885.48%
P/S Ratio
12.59
Revenue / Employee
$912,054
Employees
407
Market Cap
4.67B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 371.21M | 370.01M | 30,885.48% |
Dec 31, 2022 | 1.20M | -913.77M | -99.87% |
Dec 31, 2021 | 914.96M | 914.24M | 127,154.94% |
Dec 31, 2020 | 719.00K | -288.87M | -99.75% |
Dec 31, 2019 | 289.59M | 286.47M | 9,169.85% |
Dec 31, 2018 | 3.12M | -37.87M | -92.38% |
Dec 31, 2017 | 41.00M | 35.83M | 693.90% |
Dec 31, 2016 | 5.16M | 4.92M | 1,990.69% |
Dec 31, 2015 | 247.00K | - | - |
Dec 31, 2014 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Organon & Co. | 6.26B |
Perrigo Company | 4.66B |
R1 RCM | 2.25B |
Lantheus Holdings | 1.30B |
Haemonetics | 1.27B |
Halozyme Therapeutics | 829.25M |
Doximity | 468.33M |
Glaukos | 314.71M |
CRSP News
- 10 days ago - CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting - GlobeNewsWire
- 4 weeks ago - CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 4 weeks ago - CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting - GlobeNewsWire
- 7 weeks ago - CRISPR Therapeutics Proposes New Appointment to the Board of Directors - GlobeNewsWire
- 2 months ago - CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 2 months ago - CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit - GlobeNewsWire
- 2 months ago - CRISPR Therapeutics Announces $280 Million Registered Direct Offering - GlobeNewsWire
- 2 months ago - European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) - GlobeNewsWire